Početna stranicaKVUE • NYSE
add
Kenvue Inc
equalizerNajaktivnijeVrijednosnicaZemlja u kojoj se trguje vrijednosnicom: SADZemlja u kojoj se nalazi sjedište: SAD
Preth. zaklj. cijena
15,98 $
Dnevni raspon
15,95 $ - 16,45 $
Godišnji raspon
14,02 $ - 25,17 $
Tržišna kapitalizacija
31,27 mlr. USD
Prosječna količina
42,60 mil.
P/E omjer
21,88
Prinos dividende
5,10 %
Glavno tržište vrijednosnica
NYSE
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | lip 2025.info | Godišnja promjena |
|---|---|---|
Prihod | 3,84 mlr. | −4,02 % |
Operativni troškovi | 1,51 mlr. | −8,78 % |
Neto dohodak | 420,00 mil. | 624,14 % |
Neto profitabilnost | 10,94 | 654,48 % |
Zarada po dionici | 0,29 | −9,38 % |
EBITDA | 902,00 mil. | 4,52 % |
Efektivna porezna stopa | 28,57 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | lip 2025.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 1,07 mlr. | 5,52 % |
Ukupna imovina | 27,13 mlr. | 2,61 % |
Ukupne obveze | 16,40 mlr. | 0,84 % |
Ukupni kapital | 10,73 mlr. | — |
Dionice u optjecaju | 1,92 mlr. | — |
Cijena prema knjigovodstvenoj vrijednosti | 2,86 | — |
Povrat imovine | 7,12 % | — |
Povrat kapitala | 9,90 % | — |
Tok novca
Neto promjena novca
| (USD) | lip 2025.info | Godišnja promjena |
|---|---|---|
Neto dohodak | 420,00 mil. | 624,14 % |
Gotovina od poslovanja | 621,00 mil. | 41,14 % |
Gotovina iz ulaganja | −90,00 mil. | −5,88 % |
Gotovina iz financiranja | −548,00 mil. | −11,84 % |
Neto promjena novca | 13,00 mil. | 109,22 % |
Slobodan tok novca | 565,12 mil. | 27,86 % |
Više
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and is headquartered in the Skillman section of Montgomery Township, New Jersey, with plans to relocate its global headquarters to Summit, New Jersey.
Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index.
Kenvue employed about 22,200 people in 2022 and was first led by CEO Thibaut Mongon. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO. Wikipedia
Osnovano
23. velj 2022.
Web-lokacija
Zaposlenici
22.000
